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Abstract 18 
 19 
MET, the receptor tyrosine kinase (RTK) for hepatocyte growth factor, is a proto-oncogene involved in 20 
embryonic development and throughout life in homeostasis and tissue regeneration. Deregulation of MET 21 
signaling has been reported in numerous malignancies, prompting great interest in MET targeting for cancer 22 
therapy. The present review offers a summary of the biology of MET and its known functions in normal 23 
physiology and carcinogenesis, followed by an overview of the most relevant MET-targeting strategies and 24 
corresponding clinical trials, highlighting both past setbacks and promising future prospects. By placing 25 
their efforts on a more precise stratification strategy through the genetic analysis of tumors, modern trials 26 
such as the NCI-MATCH trial could revive the past enthusiasm for MET-targeted therapy. 27 
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The MET receptor tyrosine kinase 28 
Genesis of the MET field 29 
MET (also called c-Met or HGFR) is known as the receptor tyrosine kinase (RTK) for hepatocyte growth 30 
factor (HGF) and its functions are essential for both embryogenesis and tissue regeneration [1]. However, 31 
MET was originally discovered as a potent oncogene more than 30 years ago, and its role in cancer 32 
development has been the object of numerous studies since the initial characterization [2]. 33 
In 1984, Cooper et al. reported the identification of a chemically-induced oncogene in a human 34 
osteosarcoma cell line and suggested to name it MET, a reference to the mutagenic compound that was used 35 
in their study: N-methyl-N’-nitro-N-nitrosoguanidine [3]. While they initially mapped MET to chromosome 36 
7 and excluded any relation to other oncogenes known at the time, two more years were needed to 37 
demonstrate that the generated active oncoprotein actually was the result of the fusion of two separate loci 38 
from distinct chromosomes. This genetic rearrangement consisted of a sequence derived from chromosome 39 
1 on the 5’ end (called tpr; translocated promoter region) and a section of the MET proto-oncogene from 40 
chromosome 7 on the 3’ end, leading to the strong expression of a chimeric mRNA due to the tpr-originating 41 
sequence [4]. This resulted in the expression of a truncated cytoplasmic protein exhibiting constitutive 42 
activation because of the spontaneous dimerization enabled by the leucine zipper domain of tpr [5]. Quickly 43 
thereafter, MET was shown to have homology with both the growth factor receptor and the receptor tyrosine 44 
kinase families [6], followed by the demonstration that it was indeed the receptor tyrosine kinase for HGF, 45 
which was incidentally shown to be identical to another MET ligand called scatter factor (SF) [7].  46 
These initial discoveries laid the groundwork for the investigation into the structure and biological functions 47 
of MET, presented below. 48 
MET: gene, RNA and protein structure 49 
The locus encoding human MET is positioned on the long arm of chromosome 7 (7q31.2) and consists of 50 
24 exons transcribed into a 6637 nucleotide long mRNA, translated into a 1390 aminoacid long protein 51 
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(canonical isoform, www.ncbi.nlm.nih.gov/gene/4233). MET transcription is controlled by a variety of 52 
transcription factors: HIF-1α under hypoxic conditions, AP-1 upon HGF stimulation, members of the PAX 53 
family, NF-κB, Ets1, SP1, YB1 and the TCF family of transcription factors downstream of the Wnt pathway 54 
[2]. Additional mechanisms of regulation, including epigenetic modifications such as DNA methylation, 55 
histone acetylation and RNA interference have been studied and were summarized by Jack Zhang and Andy 56 
Babic (2015) [8]. The major mRNA isoform resulting from splicing is translated into a single 170 kDa chain 57 
in the ER [9]. Subsequently, this precursor is glycosylated in the Golgi apparatus and cleaved by furin in 58 
the post-Golgi compartment into α (50 kDa) and β (145 kDa) chains, which remain linked by a disulfide 59 
bond to form the mature form of MET. This mature MET will localize to the cell membrane with a single-60 
pass transmembrane β subunit and the α subunit being entirely extracellular [8]. Several functional domains 61 
span the length of the receptor: on the extracellular part, a SEMA domain encompasses the α and part of the 62 
β chains, followed by a PSI (plexin-semaphorin-integrin) domain and four IPT (immunoglobulin-plexin-63 
transcription factor) domains. The intracellular section of the receptor consists of a juxtamembrane (JM) 64 
domain, a tyrosine kinase (TK) domain and a carboxyl-terminal multifunctional docking site (MFDS) [10]. 65 
On the extracellular side, the SEMA domain is essential for the dimerization and activation of MET [11] as 66 
well as for binding of HGF [10], although the IPT domains have also been shown to have a high affinity for 67 
HGF binding [12]. Between these two sections, the PSI domain contains several disulfide bonds necessary 68 
for the proper orientation of the receptor towards the ligand [13]. Two regulatory phosphorylation sites 69 
reside in the JM domain, directly below the cell membrane: serine 985 and tyrosine 1003 [14,15]. The 70 
tyrosine kinase domain of MET is below the transmembrane domain and contains two tyrosine residues at 71 
positions 1234 and 1235. The phosphorylation of these sites is an essential step of the activation of the MET 72 
receptor, leading to the phosphorylation of two additional tyrosines (1349 and 1356) in the carboxyl-73 
terminal docking site, enabling recruitment of adapter proteins and transduction of the signal [16]. See 74 
Figure 1 for a schematic representation of MET. 75 
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HGF/SF: gene, RNA and protein structure 76 
HGF was initially isolated from rat platelets in 1987 and cloned in 1989 [17] while SF was independently 77 
described at the same time as a factor of cell motility [18]. The gene encoding HGF is located on 78 
chromosome 7 (7q21.11) and contains 18 exons, transcribed into a 5987 nucleotide long mRNA, itself 79 
translated into a 728 aminoacid long protein (www.ncbi.nlm.nih.gov/gene/3082). Transcriptional regulation 80 
of this locus is controlled by, among other factors, TNFα, IL-6, TGFβ, CRE, and estrogens [19]. HGF is 81 
secreted as a single chain that is proteolytically cleaved into α (69 kDa) and β (34 kDa) subunits by various 82 
proteases such as urokinase, matriptase and hepsin [20]. The two subunits remain linked by a disulfide bond 83 
and bind heparin in the extracellular matrix via the α subunit [17,21]. The α chain contains an N-terminal 84 
loop followed by four Kringle domains (K 1-4) while the β subunit is homologous to serine proteases of the 85 
chymotrypsin family but has no enzymatic activity (SPH domain) [22,23]. The α chain of HGF is sufficient 86 
for binding with the IPT domains of MET with a high affinity, but the β subunit is necessary for proper 87 
MET activation by receptor homodimerization and binds the SEMA domain with lower affinity [12,21]. 88 
See Figure 1 for a schematic representation of HGF. 89 
MET in development and tissue regeneration 90 
MET activation and signal transduction pathways 91 
As presented above, MET is a transmembrane protein activated by its homodimerization upon binding of 92 
HGF. The signaling pathways activated by this event described below affect the cellular processes presented 93 
in the next section.  94 
Upon dimerization of MET, the tyrosine residues 1234 and 1235 in the kinase domain are 95 
transphosphorylated, leading to phosphorylation of two additional tyrosine residues (1349 and 1356) in the 96 
docking domain [16]. This phosphorylated docking domain forms an SH2 recognition motif enabling the 97 
recruitment of adaptor and effector proteins such as Grb2, Gab1, SHC, CRK, PI3K, PLCγ, SHIP-2 and 98 
STAT-3 [2,16]. One remarkable difference between MET and other RTKs is that Gab1 can bind MET either 99 
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indirectly through Grb2, or directly thanks to a MET binding domain, whereas it can only bind other RTKs 100 
indirectly [24]. Acting together, these adapters either activate signaling cascades or recruit other proteins, 101 
which will themselves signal downstream. This causes the activation of pathways essential for growth, 102 
proliferation and cell motility through the following signaling cascades. Through binding and activation of 103 
the PI3K subunit p85, MET induces Akt signaling, leading to the activation of mTOR, a complex 104 
responsible for cellular growth and protein translation [16]. Additionally, Akt affects the p53 pathway by 105 
activating MDM2 while inactivating pro-apoptotic factors such as BAD and thus offers protection from 106 
apoptosis [25]. Finally, Akt activates positive cell cycle regulators such as Myc and cyclin D1 by inhibiting 107 
GSK3β [26]. Another major signaling pathway downstream of MET is the MAPK cascade. By recruiting 108 
SOS via Grb2, MET activates the small GTPase Ras, which subsequently activates Raf, a kinase responsible 109 
for the phosphorylation of MEK1/2. Activated MEK1/2 will phosphorylate the next kinases in the cascade: 110 
the Mitogen-Activated Protein Kinases (MAPK) ERK1/2. Active ERK1/2 translocate into the nucleus, 111 
where their kinase activity promotes the stabilization of transcription factors responsible for motility and 112 
cell cycle progression in the G1-S transition [27,28]. 113 
Additional pathways are activated by MET, such as the STAT-3 cascade and NF-κB signaling. STAT-3 114 
binds and is phosphorylated by MET, leading to its translocation into the nucleus where it acts as a 115 
transcription factor for several genes related to proliferation, differentiation and morphological changes such 116 
as the formation of tubules [29]. NF-κB is part of a family of rapid-acting transcription factors kept inactive 117 
in the cytoplasm by IκB, which is itself controlled by IKK. Through the PI3K-Akt pathway, MET activates 118 
IKK, which subsequently phosphorylates IκB, promoting its ubiquitination and degradation, releasing NF-119 
κB. Free NF-κB translocates into the nucleus and promotes the transcription of mitogenic, anti-apoptotic 120 
and general cell-protective genes [30]. One more signaling axis worth mentioning, as it is connected to 121 
epithelial-mesenchymal transition (EMT) via the promotion of cell migration and anchorage-independent 122 
growth, occurs through FAK via the activation of Src by MET. Activated FAK regulates cell-matrix 123 
adhesion as well as cytoskeleton reorganization and promotes cell invasion [31]. This process is assisted by 124 
the protective role of MET against anoikis, a form of cell death caused by cell detachment from the 125 
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extracellular matrix [32]. Finally, MET can also crosstalk with various other membrane proteins, forming a 126 
complex network. For instance, interaction with CD44v6, a glycoprotein involved in cell-matrix and cell-127 
cell adhesion, is required for HGF-dependent activation of MET in several cancer cell lines, is crucial for 128 
Ras activation through SOS and connects MET to the cytoskeleton [33]; α6β4 integrin, a receptor for 129 
laminin, plays a role in MET-controlled invasive growth by associating with MET and enhancing PI3K, 130 
SHC and Ras signaling [34]; and the semaphorin receptor Plexin B1, a regulator of cell-cell interaction also 131 
associates with MET to enhance its activation and thus promote invasive growth [35]. Moreover, MET has 132 
been hypothesized to protect cells from apoptosis by interacting with Fas and preventing FasL binding [36]. 133 
Under normal circumstances, MET is downregulated by various mechanisms, including negative feedbacks. 134 
Notably, active MET is phosphorylated on tyrosine 1003, leading to the recruitment of Cbl, an E3 ubiquitin 135 
ligase that will target MET degradation via two pathways: multiple monoubiquitination promotes its 136 
trafficking to the lysosome via the endosomal network for proteolytic degradation, whereas 137 
polyubiquitination promotes its proteasomal degradation [15,37]. The activation of PKC through PLCγ 138 
constitutes another negative feedback mechanism, as PKC-dependent phosphorylation of MET serine 985 139 
downregulates MET tyrosine kinase activity, whereas PP2A can dephosphorylate serine 985 and counteract 140 
the action of PKC [14]. Ubiquitin-dependent degradation of MET is not the only proteolytic mechanism 141 
downregulating MET: ADAM metalloproteases can cleave MET in the extracellular domain and cause the 142 
shedding of its ectodomain, followed by cleavage of the intracellular domain by γ-secretase [38]. This acts 143 
in two ways to downregulate MET: first by reducing the number of receptors available for HGF binding, 144 
second by releasing the ligand-binding domain of MET proteins, which will act as decoy receptors and thus 145 
reduce the amount of free HGF available for MET activation. This mechanism acts independently of MET 146 
activation and enables a constant low-grade attenuation of MET signaling [39]. Finally, several 147 
phosphatases have been shown to inhibit MET directly by dephosphorylating its tyrosine residues. Such 148 
phosphatases include PTP1B and TCPTP (which dephosphorylate tyrosines in the catalytic domain) as well 149 
as DEP1, LAR and RPTP-β (which target tyrosines in the docking domain) [40–43]. For an overview of the 150 
pathways activated by MET and their biological outcomes, see Figure 1. Altogether, this depicts MET as a 151 
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tightly regulated RTK involved in numerous cellular pathways. As MET has been shown to be crucial in 152 
many processes in embryonic development and tissue repair, these pathways have been the object of 153 
thorough studies, which are summarized in the next section.  154 
The physiological functions of MET 155 
As mentioned earlier, MET was initially discovered because of its oncogenic potential. However, the normal 156 
function of MET is to act as essential regulator of various cellular function playing a pivotal role in the 157 
development of various tissue types, as well as an important factor for tissue repair [1]. 158 
MET is mostly expressed by epithelial cells of various tissues and organs (including the gastrointestinal 159 
tract, lung, liver, kidney, thyroid and skin) as well as some endothelial cells, cells in the hematopoietic 160 
lineage, B cells and in neurons of various brains structures, while HGF is mainly expressed and secreted by 161 
mesenchymal cells such as fibroblasts as a cytokine that modulates the proliferation of epithelial cells [44–162 
49]. As the other name of HGF – scatter factor – suggests, it also affects the “scattering” of MET-expressing 163 
cells and controls invasive growth by its motogenic, mitogenic and morphogenic properties [50]. MET acts 164 
as the main coordinator of the various stages of this complex program that involves proliferation, matrix 165 
degradation, survival and migration: together MET and HGF form the basis for epithelial and mesenchymal 166 
interaction, wound closure and angiogenesis at various stages of life [51]. As such, MET signaling is 167 
essential in vivo: deletion of HGF was shown to impair proper placental and fetal development in mice, 168 
leading to in utero death. Among the affected tissues, liver was strongly impacted and showed drastic size 169 
reduction [52]. By virtue of being expressed in many more organs, MET signaling is key for the 170 
development of additional types of tissues, including the pancreas, muscles and various types of neurons 171 
[53–55]. It regulates angiogenesis by promoting VEGF signaling while downregulating TSP-1, and thus 172 
stimulating endothelial cell motility [45,56], and can also promote hematopoiesis [46]. As a token of the 173 
pleiotropic functions of MET, a recently discovered mutation in the fourth IPT domain (F841V) has been 174 
linked to hearing loss in humans [57]. 175 
9 
 
MET functions are not limited solely to development: by promoting proliferation and invasion, it is a crucial 176 
component of wound repair when the invasive growth of remaining cells needs to be reactivated to 177 
reconstitute the damaged tissues. Along with other factors, MET signaling plays a key role in liver and 178 
kidney regeneration [58,59]. Bone remodeling also involves MET signaling as both osteoclasts and 179 
osteoblasts express MET and osteoclasts secrete HGF, leading to a crosstalk between these cell types to 180 
ensure proper bone resorption and deposition [60]. Beyond its functions directly involved in repair, MET 181 
signaling plays a protective role in damaged tissues (such as ischemic cardiac muscle) by protecting cells 182 
from apoptosis [61]. As a whole, the HGF-MET tandem can be described as a crucial factor for cellular 183 
proliferation, growth and motility. While these functions are essential for normal life, they can be hijacked 184 
to support cancer development, which will be described in the next section. 185 
The oncogenic facet of MET: a key player in cancer development and 186 
progression 187 
Mechanisms of MET/HGF deregulation 188 
The initial discovery of MET was made by the generation of an artificially induced oncogenic fusion protein, 189 
and while this particular rearrangement was later also observed in human gastric cancerous lesions, a 190 
plethora of different mechanisms leading to MET deregulation can naturally occur at all stages of 191 
carcinogenesis and caught the interest of researchers promptly after the initial discovery of tpr-MET [62]. 192 
Various mechanisms have been shown to lead to MET deregulation in cancer, the most obvious one being 193 
HGF-dependent: the stromal cells surrounding tumors frequently express HGF [63]. Ligand-dependent 194 
activation of MET sometimes happens in an autocrine instead of paracrine fashion, however the 195 
overexpression of MET is sometimes necessary for tumor cells to respond to HGF [64,65]. As a matter of 196 
fact, MET overexpression is the most frequent cause of its constitutive activation in a ligand-independent 197 
manner and results mostly from transcriptional upregulation. Examples of this have been reported in a 198 
breadth of distinct carcinomas including thyroid, colorectal, ovarian, pancreatic, lung, and breast cancer 199 
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[66–71]. Hypoxia is one of the mechanisms that can trigger increased transcription of MET: as mentioned 200 
above, HIF-1α can promote the transcription of MET [72]. Interestingly, MET overexpression can occur as 201 
a response to radiotherapy through the ATM-NF-κB signaling pathway [73]. Activation of other oncogenes, 202 
such as Ras, can upregulate MET expression as well [74]. A less common way for tumor cells to overexpress 203 
MET is the amplification of its locus. Such gene amplification has been reported in esophageal 204 
adenocarcinoma, medulloblastoma, cancer of the pancreas and of the gastrointestinal tract [75–78]. In lung 205 
adenocarcinomas, MET amplification has also been documented as an acquired resistance mechanism to 206 
EGFR targeted therapy [79]. Activation of MET due to its overexpression is thought to happen through its 207 
spontaneous dimerization via the SEMA domain and is linked to cell-matrix adhesion mechanisms. [69,80]. 208 
However, some tumors rely on point mutations to activate MET without overexpressing it. The relevance 209 
of activating MET mutations is underscored by the evidence that in HNSCC, the selection of somatic MET 210 
mutations is promoted during metastatic spread [81]. These genetic aberrations include mutations in the 211 
kinase domain of MET and have been described in both hereditary and sporadic forms of papillary renal 212 
cell carcinomas as well as in gastric cancer [82,83]. Many of these mutations have been thoroughly studied 213 
by their ectopic expression in various cellular systems, such as the NIH 3T3 mouse fibroblast model [84].  214 
Ineffective downregulation of MET through the inactivation of pathways leading to MET dephosphorylation 215 
or degradation can also lead to increased MET activation [85]. A relevant example of these mechanisms is 216 
seen in a family of mutations leading to alternative splicing and hence skipping exon 14 of MET. The 217 
resulting protein lacks a section of the juxtamembrane domain containing serine 985 and tyrosine 1003 218 
which, as previously mentioned, are capital for the downregulation and degradation of MET [86]. These 219 
mutations were first observed in lung cancer cases as a response mechanism to EGFR inhibition by MET 220 
activation, and were later detected in subpopulations of brain and gastric cancer patients [87]. While a 221 
relatively rare mutation, it could serve as a biomarker for patient stratification, as presented in later sections 222 
of this review. 223 
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Finally, MET activation can result from the activation of other RTKs. For instance, stimulation of EGFR 224 
with its ligand EGF promotes MET activation via the MAPK signaling pathway when both RTKs are co-225 
expressed [88]. Another example is RON, an RTK structurally related to MET. These receptors can interact 226 
together and are sufficiently similar for the activation of one to lead to the phosphorylation of the other [89]. 227 
Similarly, several other RTKs, including IGF-1R and AXL, can interact with MET and cause its activation 228 
[90,91].  229 
The significance of MET in cancer: a prognostic marker and a target 230 
MET deregulation can happen at any stage of cancer development, and together all the activation 231 
mechanisms presented above have been shown to promote both primary tumor formation and the transition 232 
to metastatic disease [66]. Various studies have associated high MET expression and activation with poor 233 
outcome [92]. For instance, high expression is known to correlate with markers of negative prognosis in 234 
thyroid carcinoma, is a significant negative prognostic marker in NSCLC and is a predictor of tumor 235 
invasion and lymph node metastases in colon cancer [93–95]. These last two examples are representative of 236 
two classes of cancer that are of particular interest in the context of MET: gastrointestinal and lung cancers. 237 
While MET mutations or amplifications are rare in gastric and colorectal cancer (CRC), overexpression of 238 
MET and HGF at the mRNA and protein levels is common and can be observed in up to 40-70% of patient 239 
samples, correlates with tumor stage and is a prognostic marker of clinical outcome [66,96–99]. Moreover, 240 
MET expression is a predictor of invasive growth in gastric cancers and is associated with higher 241 
occurrences of lymph node and liver metastases [32,95,100]. Cellular and in vivo models of gastric and 242 
colorectal cancer have confirmed these observations and show that blockade of MET signaling reduces 243 
tumor growth and spread [32,101–103]. Overall, while the various methods and scoring systems used to 244 
assess MET-positivity make the prognostic value of its aberrant expression difficult to gauge, systematic 245 
reviews and meta-analyses associate high MET expression with higher hazard ratios and poor prognosis in 246 
gastric and colorectal cancer [104]. Interestingly, MET amplification has been observed as a resistance 247 
mechanism to EGFR inhibition in metastatic colorectal cancer, a phenomenon that can also occur in 248 
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NSCLC, either by selecting for pre-existing MET-amplified subclones or by inducing de novo copy number 249 
gains [105,106]. Lung cancer studies also led to the discovery of another clinically relevant phenomenon: 250 
MET exon 14 skipping mutations [107]. Because of such genetic aberrations, MET is considered a major 251 
oncogene and a potential target in NSCLC [108]. Indeed, there is evidence for the efficacy of MET-targeting 252 
therapies in NSCLC cases exhibiting MET alterations [86]. 253 
A more global picture of the role of MET in cancer depicts this RTK as an overall negative factor. Combined 254 
data from multiple studies accessed from the cBioPortal website reveal that MET genetic alterations are 255 
common in various types of cancers (Figure 2A), the highest mutation rate is observed in lung cancers 256 
whereas esophageal squamous cell carcinomas show the highest amplification rate. RNA sequencing shows 257 
overexpression in all cancer types: the highest median expression is found in papillary renal cell carcinoma 258 
(PRCC), often combined with amplification or copy number gain, and the lowest overexpression is seen in 259 
acute myeloid leukemia (AML) (Figure 2B). Strikingly, disease outcome is significantly worse for cases 260 
with MET alterations compared with non-altered MET, showing a median overall survival of 66.7 versus 261 
92.4 months (Figure 2C). 262 
As will be discussed further below, these observations have led to a great interest in the development of 263 
MET targeting compounds, in particular for the treatment of MET-addicted tumors, as covered by various 264 
reviews [80,109]. 265 
MET as an addicting oncogene 266 
Oncogene addiction, an expression that was first coined by Bernard Weinstein in 2002, denotes the fact that 267 
despite having multiple genetic alterations, the survival and proliferation of some tumor cells rely 268 
exclusively on one (or a few) specific oncogenes, the earliest examples being Myc, Ras, Bcr-Abl and 269 
HER2/neu [110–114]. Thus, the inhibition of the addicting oncogene is often sufficient to induce 270 
proliferative arrest, senescence, apoptosis or terminal differentiation in addicted cancer cells [115]. While 271 
this phenomenon was first observed in artificial models, this field of research was quickly translated to 272 
applicable treatment strategies in the clinic with oncogene-targeted therapies. Imatinib, a specific inhibitor 273 
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of Bcr-Abl, the product of the Philadelphia chromosome translocation and a cause of chronic myeloid 274 
leukemia, showed remarkable efficacy in patients [116]. Similarly, inhibition of HER2 with the monoclonal 275 
antibody trastuzumab was shown to be efficacious and well tolerated in breast cancer patients displaying 276 
strong overexpression of the receptor [117]. Over the years, evidence has emerged that oncogene addiction 277 
can occur in many types of cancer and for several oncogenes, including major RTKs such as EGFR, VEGFR 278 
and KIT [118]. Numerous clinical trials have shown the efficacy of targeted therapies against EGFR in lung 279 
cancers driven by that oncogene, significantly improving progression free-survival (PFS) compared to 280 
standard of care, but most trials failed to show higher overall survival [119–122]. Similarly, additional 281 
examples of therapies targeting addiction to various oncogenes, both in preclinical and clinical trials, have 282 
shown strong early response but failed to elicit durable effects [123]. This can be explained by the 283 
development of resistance to the therapeutic compound via one or several mechanisms including the 284 
selection or acquisition of protective mutations in the target and the escape from addiction, relying instead 285 
on other pathways or oncogenes for cancer cell survival and proliferation, highlighting the need for 286 
combination therapy [118,124,125]. As emphasized previously, MET is a potent oncogene involved in 287 
various stages of neoplastic and metastatic development as well as in resistance mechanisms to therapies 288 
targeting other oncogenes. Moreover, there is evidence for MET addiction in the preclinical and clinical 289 
settings, making this receptor a prime target for targeted therapy [80]. For instance, the MET inhibitor PHA-290 
665752 has proven remarkably efficient in inducing apoptosis in gastric cancer cell lines harboring 291 
amplification of wild-type MET, while sparing cell lines without copy number alterations [103]. Similarly, 292 
out of a panel of 35 human cancer cell lines, the eight lines with the highest expression of active MET were 293 
shown to be significantly sensitive to the MET-targeting antibody ABT-700 [126]. While the most 294 
promising results of MET-targeting therapies have been observed in the preclinical setting, their potential 295 
translational application is supported by case reports describing encouraging results for their use in MET-296 
amplified lung and gastric cancer patients [127–129]. 297 
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Targeting MET in the clinic: tools, trials, troubles and tentative 298 
treatments 299 
Many angles of attack have been used to target the HGF-MET signaling axis in cancer cells. A wide variety 300 
of compounds have been developed, such as decoy ligands, docking site blockers and chimeric ribozyme 301 
constructs leading to the degradation of MET mRNA [130–132]. However, such strategies have not been 302 
clinically tested at this point. Therefore, the main focus of this section will be the two most commonly used 303 
categories of compounds: antibodies targeting either HGF or MET, and small molecules inhibitors of MET.  304 
Antibodies targeting HGF and MET 305 
Targeting oncogenes with antibodies is sometimes viewed as preferable than the use of small molecule 306 
inhibitors because antibodies can be more specific, are usually well tolerated, can elicit cumulative cellular 307 
responses and have longer half-lives, but need to be administered intravenously whereas small molecule 308 
inhibitors are available orally and can target receptors regardless of their mechanism of activation (ligand-309 
dependent or -independent) [2,133]. There currently is a number of humanized and fully human monoclonal 310 
antibodies (mAbs) targeting MET or HGF in development or in clinical trials. The main mechanism of 311 
action of anti-HGF mAbs is to prevent the binding of HGF to MET by targeting domains required for their 312 
interaction. Antibodies targeting MET can act similarly to prevent HGF binding, but have also shown 313 
indirect mechanisms of actions such as receptor degradation or downregulation and immune-mediated 314 
antibody-dependent cellular cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC) [133]. 315 
HGF-targeting mAbs include the fully human IgG2 rilotumumab (AMG 102, Amgen, Thousand Oaks, 316 
California, USA) preventing interaction with MET by targeting the SPH domain of HGF [134], the 317 
humanized IgG1 ficlatuzumab (AV-299, Aveo Pharmaceuticals, Cambridge, Massachusetts, USA) [135], 318 
and the mAb L2G7 (Galaxy Biotech, Sunnyvale, California, USA)/TAK-701 (Takeda pharmaceutical, 319 
Osaka, Japan) [136], all of which are under clinical investigation. Additional anti-HGF antibodies are also 320 
15 
 
being studied at the preclinical level, such as SFN68, which binds HGF in complex with MET, and the 321 
bispecific (MET- and serum albumin-binding) nanobodies 1E2-Alb1 and 6E10-Alb8 [137,138]. 322 
As mentioned before, MET targeting antibodies can elicit diverse cellular responses depending on their 323 
nature and the domain they bind. R13 and R28 (OncoMed Pharmaceuticals, Redwood city, California, USA) 324 
are fully human mAbs used in tandem that compete with HGF for binding and induce ADCC [139]. 325 
SAIT301 (Samsung Inc, Yongin, Republic of Korea) is a humanized mAb that leads to MET downregulation 326 
by internalization and lysosomal degradation via LRIG1 [140]. Similarly, emibetuzumab (LY2875358, Eli 327 
Lilly, Indianapolis, Indiana, USA) is a humanized IgG4 that induces internalization and degradation of MET 328 
and prevents HGF binding [141]. ABT-700 (AbbVie, Lake Bluff, Illinois, USA) is a humanized IgG1 that 329 
blocks HGF binding and induces ADCC by recruiting natural killer cells to mediate the lysis of the targeted 330 
cells [126]. An antibody-drug conjugate (ADC) has been developed from ABT-700: ABBV-399 (AbbVie). 331 
This ADC is composed of the antibody and the cytotoxic microtubule inhibitor monomethylaurstatin E, 332 
connected by a cleavable linker. Using an ADC could present the advantage of efficiently targeting cancer 333 
cells with high expression of MET regardless of MET activation or addiction, while sparing normal cells 334 
expressing lower levels of MET [142]. Onartuzumab (MetMab/OA-5D5, Genentech, South San Francisco, 335 
California, USA) is a humanized monovalent antibody that competes with HGF by binding to the SEMA 336 
domain of MET [143]. DN30 (Metheresis Translational Research SA, Lugano, Switzerland) is a chimeric 337 
mouse IgG2A that induces ADAM-10 mediated shedding of receptor by binding the 4th IPT domain of MET 338 
and altering the conformation of the receptor, which has the benefit of preventing MET activation and 339 
releasing decoy MET moieties that can titer HGF away from cancer cells. The original form of the 340 
compound had a flaw common to several receptor-targeting antibodies: since antibodies contain two binding 341 
domains, DN30 could act as a partial agonist of MET by bringing two receptors together, leading to ligand-342 
independent dimerization and activation. This issue was solved by converting the compound to a smaller 343 
monovalent Fab (MvDN30), which unfortunately had an increased renal clearance due to its small size 344 
[144]. Two strategies could be explored to solve the resulting shorter half-life: stabilizing the plasma 345 
availability of the compound (for example by PEGylation) or enabling continuous production of the Fab in 346 
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patients by gene transfer therapy, a route that is investigated in preclinical models of glioblastoma 347 
multiforme, where MET has been described as a marker of cancer stem cells [145]. 348 
Small molecule inhibitors of MET 349 
As mentioned earlier, small molecule tyrosine kinase inhibitors (TKIs) have the benefit of targeting the 350 
activated receptor regardless of ligand presence by preventing ATP from reaching the ATP-binding pocket 351 
of the kinase domain [146]. However, TKIs can vary in their specificity: some compounds have 352 
demonstrated remarkable specificity for MET while others inhibit several kinases with varying affinities. 353 
One notable exception to the ATP-competitive mode of action is the case of Tivantinib (ARQ197, Daiichi 354 
Sankyo, Tokyo, Japan, and ArQule Inc, Woburn, Massachusetts, USA), which was initially presented as an 355 
allosteric inhibitor of MET locking the receptor in the inactive conformation, but has subsequently been 356 
shown to exert its cytotoxic activity by interfering with microtubule dynamics without affecting MET 357 
activation [147]. Table 1 lists relevant examples of non-selective and selective TKIs that are at various 358 
stages of clinical trials [2,109]. 359 
MET/HGF targeting in clinical trials 360 
Over the years, many of the compounds presented above have progressed through clinical trials with varying 361 
degrees of success. While there are too many completed and ongoing trials to be comprehensively presented 362 
here, previous reviews have regularly summarized their progress, and only the most relevant examples of 363 
completed or ongoing studies are highlighted below [2,80,109,133,146,148]. It should be noted that 364 
currently only two non-selective MET TKIs have been approved for use, but not specifically for their MET-365 
inhibiting action: cabozantinib for medullary thyroid cancer and kidney cancer, and crizotinib for ALK and 366 
ROS1 positive NSCLC [149,150]. However, these and other compounds are still being evaluated for other 367 
cases, with many trials focusing on lung and gastrointestinal cancers due to the role this signaling axis plays 368 
in the development and progression of these malignancies, as mentioned earlier. Nonetheless, a number of 369 
studies is also being performed for other types of cancer, such as HCC, castration-resistant prostate cancer, 370 
renal cell carcinoma or metastatic melanoma [151]. Altogether, these trials have produced mixed results for 371 
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the use of MET/HGF-targeting compounds in the clinic. As mentioned earlier, the main mechanism of MET 372 
activation is ligand-independent and relies on the overexpression of the receptor, explaining why the 373 
majority of the currently explored strategies focus on targeting MET rather than HGF. However, HGF-374 
targeting compounds have also been investigated and notable examples are presented below. 375 
The anti-HGF mAb rilotumumab has undergone phase III clinical trials (RILOMET-1 and 2, NCT01697072 376 
and NCT02137343) as first-line therapy in patients with advanced MET-positive gastric and 377 
gastroesophageal cancer, in combination with ECX chemotherapy. Unfortunately, after the promising 378 
results of a phase II trial, the RILOMET studies showed that the addition of rilotumumab to chemotherapy 379 
performed worse than chemotherapy alone, leading to the early termination of the trials [152,153]. Similarly, 380 
the phase II MEGA study compared the combination of rilotumumab plus mFOLFOX6 versus mFOLFOX6 381 
alone as a first-line treatment for HER2-negative advanced gastric and gastroesophageal cancer but failed 382 
to show improvements with the addition of rilotumumab (NCT01443065). 383 
The phase III METGastric study evaluated the benefits of the addition of onartuzumab to mFOLFOX6 as a 384 
first-line treatment of MET-positive but HER2-negative metastatic gastric and gastroesophageal 385 
adenocarcinoma, but failed to show any significant improvement [154]. A promising phase II clinical trial 386 
studying the addition of onartuzumab to EGFR inhibition for the treatment of advanced NSCLC showed 387 
benefit in the MET-positive population, but failed to confirm this result in a subsequent phase III trial. Two 388 
hypotheses have been proposed to explain this unfortunate turn of events: compounds preventing the 389 
interaction between MET and HGF might be ineffective in this setting (for example in the case of ligand-390 
independent activation of MET), or the biomarkers used for patient recruitment were inadequate [155,156]. 391 
The results of additional phase III studies are still pending. 392 
Crizotinib, as mentioned before, is a multitarget inhibitor and has been approved for the treatment of NSCLC 393 
expressing the fusion proteins EML4-ALK or CD74-ROS1, two types of cancer where its efficacy was 394 
demonstrated [149,150]. However, its pertinence as a MET inhibitor is still being evaluated. Early results 395 
of a Crizotinib trial showed some promise for the treatment of NSCLC harboring MET exon 14 skipping 396 
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mutations [157]. The phase I PROFILE 1001 trial has also been testing the efficacy of this compound in 397 
lung cancer and other solid tumors exhibiting MET, ALK or ROS1 alteration. While the study is still 398 
ongoing, preliminary results have shown benefits for patients with advanced, ROS1-rearranged or MET-399 
amplified NSCLC [158,159]. Likewise, several ongoing phase II trials are evaluating the performance of 400 
crizotinib in NSCLC and other cancers, focusing on genetic alterations such as MET amplification and 401 
mutation (NCT02034981, NCT02499614, NCT03088930). Similar trials are also being performed for 402 
gastric cancer: a pilot phase I study showed that MET-amplified gastroesophageal adenocarcinoma could 403 
transiently respond to crizotinib [160], the subsequent phase II study has yet to publish conclusions 404 
(NCT02435108). At the present time, the phase I MErCuRIC1 trial represents a first attempt at combining 405 
crizotinib with a MEK inhibitor in a cohort of CRC patients harboring amplified MET and either wild-type 406 
or mutated Ras (NCT02510001) [161].  407 
Cabozantinib is the second non-selective MET inhibitor that has been approved for use in the clinic: for 408 
advanced, unresectable medullary thyroid cancer and for kidney cancer as a second-line treatment after anti-409 
angiogenic therapy [162,163]. As for crizotinib, the approved use of cabozantinib does not involve the status 410 
of MET in the tumor. There is currently limited evidence for the benefit of using cabozantinib specifically 411 
to target MET: a case report presented one patient with MET exon 14 skipping who showed complete 412 
response, and the phase III CELESTIAL trial in HCC, a disease where MET has been implicated, showed 413 
a slight but significant improvement in PFS and overall survival for patients treated with cabozantinib, but 414 
did not report on a MET-specific response [157,164–166]. Several phase II trials are currently testing 415 
cabozantinib specifically for lung and salivary gland cancer harboring MET alterations (NCT03729297, 416 
NCT01639508, NCT03911193, NCT02132598). 417 
Selective MET inhibitors are also being investigated in clinical trials, with some studies specifically 418 
focusing on the status of MET in the tumors. Capmatinib displayed improvements for patients with MET-419 
overexpressing or amplified NSCLC in a phase I trial, and a phase Ib/II study with EGFR-targeted therapy-420 
resistant NSCLC showed benefits for tumors having high MET copy number gains [167,168]. Numerous 421 
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phase II trials are currently testing Capmatinib in MET-dysregulated NSCLC and HCC (NCT03693339, 422 
NCT02750215, NCT01737827, NCT01610336, NCT02414139, NCT02276027). 423 
Tepotinib had an antitumor effect in a phase I study, which led to the start of a phase I/II study in MET-424 
positive HCC as an alternative to sorafenib (an inhibitor of VEGFR) [169–172] and the opening of the 425 
recruitment for a phase II trial in advanced NSCLC harboring MET exon 14 skipping mutations or MET 426 
amplification (NCT02864992). Recently, a trial has been set up to assess the combination of tepotinib with 427 
a 3rd generation EGFR inhibitor to treat EGFR-mutated, MET-amplified NSCLC having acquired resistance 428 
to EGFR inhibitors (NCT03940703). 429 
AMG 337 has been evaluated in a phase I trial for various advanced malignancies where it elicited a 430 
favorable response in MET-amplified tumors [173]. Unfortunately, the following phase II study was 431 
terminated early after an intermediate review revealed that the treatment had a lower-than-expected activity 432 
compared to the phase I trial, despite the selection of patients exhibiting MET amplification [173]. Another 433 
phase II study is currently recruiting patients with advanced or metastatic solid tumors harboring MET 434 
overexpression or exon 14 skipping mutations (NCT03147976). 435 
 Savolitinib is involved in numerous trials at different stages, including a phase II study in lung cancer, 436 
selecting for MET exon 14 mutated cases (NCT02897479), and several phase I/II studies in advanced gastric 437 
adenocarcinoma or metastatic CRC with MET overexpression as second- or third-line treatment, alone or 438 
combined with docetaxel (NCT03592641, NCT02449551, NCT02447380). Of note, savolitinib is also 439 
being evaluated in a phase III study in MET-driven, unresectable, locally advanced or metastatic PRCC 440 
(NCT03091192), following a promising phase II trial in a similar setting where HGF mutations or MET 441 
alterations correlated with better response (NCT02127710) [174]. 442 
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The road ahead: better aiming, or better weapons? 443 
The stratification struggles 444 
Patient stratification for targeted therapy is not always a trivial affair: some targets can be more difficult to 445 
select than others. Whereas HER2 amplification is a common phenomenon in breast and gastric cancer (15-446 
30% and 21-33%, respectively) [175], leading to a large population in which treatment options such as 447 
trastuzumab and lapatinib have been tested and validated, true MET amplification is a rarer occurrence. 448 
Similarly, activating mutations are less frequently observed in MET than in EGFR, which can be mutated 449 
in up to 15% of Caucasian NSCLC patients [176]. Unlike these two examples, MET alterations have been 450 
detected in less than 10% of the cases for most cancer types (see Figure 2A), and this comparatively low 451 
MET alteration frequency makes it a challenging candidate for stratification. Furthermore, not all MET 452 
alterations might lead to sensitization to targeted therapy. A recurring question in the field of targeted 453 
therapy is the validity of the target: specific kinase inhibitors can only work if the corresponding kinase is 454 
essential to the growth and survival of the cancer cells [110,118]. Such oncogene addiction can be difficult 455 
to establish outside of a preclinical cellular model, and the setbacks from early clinical trials targeting MET 456 
could have resulted from inappropriate patient selection. Indeed, patient stratification was often initially 457 
made based on MET expression in the tumor, regardless of MET activation (denoted by the phosphorylation 458 
of MET tyrosines 1234/1235), potentially rendering MET targeting ineffective [177]. Indeed, only a fraction 459 
of MET positive tumors are actually p-MET positive [178]. One would think that assessing MET 460 
phosphorylation instead of MET expression in the tumor would be a simple solution to that problem. 461 
Unfortunately, the detection of phosphorylated MET by immunohistochemistry (IHC) remains complicated: 462 
unless extreme precautions are taken in the processing of the tissue and the detection process, the 463 
phosphorylation can be lost [179]. Research from Huang and colleagues highlights the complexity of 464 
defining the proper way to measure MET expression and activation by IHC on archival tissue, their work 465 
suggests that every type of cancer might need a specific companion diagnostic, potentially each with a 466 
different antibody [180]. 467 
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Early trials have been criticized for casting too wide a net by selecting patients using MET detection by IHC 468 
[181]. Therefore, the focus shifted to the detection of genetic alterations showing a better correlation with 469 
the response to MET-targeted therapies, such as MET amplification or MET exon 14 skipping mutations. 470 
However, MET amplification assessment by fluorescence in situ hybridization (FISH) is controversial as 471 
well. Some trials deem that duplication of the whole chromosome 7 is not enough to depict true MET 472 
amplification, and consider that only the amplification of the MET locus, defined by a high ratio of MET to 473 
centromere 7 (MET/CEP7), represents an oncogenic event [181]. What MET/CEP7 threshold should be 474 
applied remains controversial: some trials selected patients with a ratio higher than 2, whereas others defined 475 
MET amplification as a MET/CEP7 higher than five, the most stringent threshold suggesting that less than 476 
1% of the patients might exhibit true amplification, whereas less stringent settings include up to 7% in the 477 
MET-amplified group in gastric or lung cancer studies [181,182]. The stratification of patients harboring 478 
MET exon 14 skipping mutations, which is already being applied in some trials as presented above, could 479 
be a viable alternative selection strategy, enabled by the non-intrusive detection in circulating tumor DNA 480 
[157,179]. Nevertheless, it is important to remember that MET exon 14 skipping only occurs in up to 4% 481 
of NSCLC cases, and selecting such a small subset of patients could exclude other potential responders 482 
[183].  Regardless of the stratification method, it has become clear that only a minute fraction of tumors 483 
exhibit MET addiction, and thus the potential response to standard anti MET treatments might only prove 484 
effective for a very limited population [157,181]. However, recent advances in the field of immunotherapy 485 
could extend MET targeting therapies to tumors expressing MET without addiction to the oncogene, as 486 
presented in the next section. 487 
The rise of personalized immunotherapy 488 
The generation and injection of chimeric antigen receptor (CAR) T-cells is a type of adoptive 489 
immunotherapy and a promising method currently being developed for the treatment of cancer. The 490 
principle behind CAR T therapy is the genetic engineering of a patient’s T-cells ex vivo to express an 491 
artificial receptor (CAR) targeting a surface protein specifically expressed by the targeted tumor cells. 492 
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Modified T-cells are then infused into the patient, where they can target tumor cells independent of the 493 
major histocompatibility complex and trigger tumor cell death primary by cytolysis and by extrinsic 494 
apoptosis induction [184]. Thus, as opposed to TKIs and mAbs which can only affect MET-addicted cells 495 
or cells that express high levels of MET, this therapeutic approach can potentially be used to target cells 496 
expressing the target at a level too low for standard targeted therapy, or those that are not addicted to the 497 
target [185,186]. Currently, CAR T-based therapies have shown the most promise for hematologic 498 
malignancies, while their application to solid tumors remains a challenge [187]. Nevertheless, efforts are 499 
being made to target proteins such as EGFR [188], EphA2 [189] and HER2 [190]. Similarly, MET has been 500 
the object of recent studies evaluating its potential as a CAR T target. In order to overcome the challenge of 501 
solid tumor invasion by T-cells, Tchou and colleagues assessed the feasibility of intratumoral injection of 502 
MET-targeting CAR T-cells for the treatment of metastatic breast cancer. Intratumoral injection has the 503 
added benefit of reducing on-target off-tumor effect, which was further lessened by the transient expression 504 
of the CAR. After observing tumor control with this approach in a mouse xenograft model, six patients were 505 
enrolled for a phase 0 trial. All patients treated presented MET-positive tumors and the injection of CAR T-506 
cells was well tolerated. While no clinical response could be measured, systemic dissemination of CAR T-507 
cells remained limited and histological analysis of the sites of injection revealed the induction of necrosis, 508 
immune cell infiltration and loss of MET-positive cells. This trial was limited in its scope, but serves as an 509 
encouraging proof of concept, opening the door to further studies with larger cohorts and proper controls to 510 
evaluate the efficacy of MET-targeting CAR T therapies [191]. While the study by Tchou et al. generated 511 
a CAR with the single chain variable fragment of an antibody (onartuzumab), other approaches have also 512 
been described. Thayaparan and colleagues generated a CAR by using the NK1 domains of HGF, hijacking 513 
a natural MET-binding mechanism. They applied this approach to the treatment of mesothelioma and 514 
showed positive results in vitro with MET-expressing cell lines. They also showed the safety and efficacy 515 
of locally injected MET-targeting CAR T-cells in an intraperitoneal mouse xenograft model, leading to 516 
tumor regression, albeit only when injecting high doses of CAR T-cells [192]. These promising early results 517 
warrant further research into the efficacy of such therapies in the clinical setting, however the monitoring 518 
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and management of toxicity remains a crucial parameter to promote the application of CAR T therapies 519 
[187]. 520 
Conclusion: the past, present and future of MET signaling-targeted 521 
therapies 522 
As presented in this review, the results of MET/HGF-targeting agents in clinical trials are underwhelming. 523 
However, lessons can be learned from both successes and failures, which should help design future trials 524 
with improved patient selection and drug combinations. It could be remarked that antibody-based therapies 525 
seem to fare worse than small molecule inhibitors. However this might stem from an inferior patient 526 
selection process, as it was often made on the basis of MET expression measured by IHC, a technique that 527 
has limitations due to variables such as fixation and processing of the tissue or subjectivity in the scoring 528 
[193]. Furthermore, measuring MET expression has the downside of not necessarily correlating with MET 529 
activation, denoted by phosphorylation of tyrosine residues. Despite evidence that the presence of 530 
phosphorylated MET is associated with tumor progression and is a predictor of metastasis and survival in 531 
some types of tumors, assessing MET activation or addiction in this fashion has not been widely adopted 532 
for patient accrual [194,195]. As is seen for EGFR-targeting therapies, where efforts are made to enrich for 533 
patients with activating EGFR mutations, screening patients for genetic alterations that are associated with 534 
MET activation (notably MET exon 14 skipping mutation and MET amplification), rather than simply 535 
measuring MET expression, is now considered a superior selection strategy and predictor of response to 536 
MET inhibition in the case of NSCLC [86,157,196,197]. Indeed, ambitious efforts are currently being made 537 
to improve personalized therapy: the MATCH phase II clinical trial is aiming at stratifying patients by 538 
genetic alteration instead of histology to provide them with the appropriate treatment, such as crizotinib in 539 
the presence of MET overexpression or exon 14 mutations [198,199]. 540 
Another lesson can be learned from EGFR-targeting therapies: the inevitable rise of resistance, for example 541 
as a result of the acquisition of a mutation (e.g. EGFR T790M) that can null the effect of the TKI or by 542 
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relying on another RTK such as MET [200]. In the case of EGFR, this has been addressed in two ways: 543 
either by using more recent inhibitors that can overcome the protective effect of the mutation, such as 544 
osimertinib, or by combining EGFR and MET inhibition [197,201]. Similar approaches could be effective 545 
to face the expected emergence of resistance to MET-targeting compounds. Several such resistance 546 
mechanisms in MET-driven tumors and cell lines have been documented and include the selection of 547 
preexisting subclones harboring MET Y1248H (or Y1248C) mutations, rendering cells resistant to 548 
crizotinib, or MET D1228V, protecting against savolitinib. While these mutated variants of MET can be 549 
inhibited by glesatinib or cabozantinib, respectively, additional mutations could be selected or acquired in 550 
treated cells and render them resistant to virtually any inhibitor [202–204]. Resistance to MET inhibition 551 
can also occur through the amplification of HER2 or FGFR2 and de novo Ras mutations, which would 552 
require the combined use of several targeted therapies preemptively or after relapse [205,206]. Drug 553 
combinations can also be rationally designed to directly target processes that involve several RTKs. One 554 
such example would be the combination of VEGFR and MET inhibitors, as both are involved in 555 
angiogenesis [130,207]. Interestingly, such a combination could be necessary to overcome the unforeseen 556 
activation of MET by the inhibition of VEGFR in a particular setting. Indeed, targeting VEGFR in 557 
glioblastoma multiforme can have the unexpected effect of enhancing MET activation, leading to a more 558 
invasive tumor phenotype [208]. 559 
Altogether, despite middling success, preclinical and clinical studies show potential for MET as a 560 
therapeutic target, provided improvements in patient stratifications are made. The recent development of 561 
MET targeting immunotherapy and the granting by the FDA of a priority status to both capmatinib and 562 
tepotinib, based on the promising results of the GEOMETRY mono-1 (NCT02414139) and the VISION 563 
(NCT02864992) studies, highlight that MET remains an appealing target and could renew interest in this 564 
oncogene. Since the resistance to the inhibition of various oncogenes (such as EGFR, BRAF, MEK or 565 
FGFR) can arise through the activation of MET [109], looking forward, one can expect the development of 566 
combination therapies that could pre-emptively address resistance and have a synergistic effect with MET-567 
targeting therapies.  568 
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Figure and Table legends 1114 
Figure 1. Schematic representation of the subunits, domains and known phosphorylation sites of MET and 1115 
HGF, as well as major signaling pathways downstream of MET. 1116 
 1117 
 1118 
  1119 
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Figure 2. Summary of MET alterations frequency and outcome in different cancer types. Visualization of 1120 
the data generated on cBioportal.org [209,210] from 212 studies (see link for detailed list: 1121 
https://www.cbioportal.org/results/cancerTypesSummary?session_id=5d78f196e4b058f36688adc1, last 1122 
accessed on the 11th of September 2019)  1123 
A. Frequency of MET genetic alterations in various cancer studies (studies with an alteration frequency 1124 
lower than 1% have been excluded from the graph). 1125 
B. MET RNA expression in various types of cancer. 1126 
C. Kaplan-Meier graphs showing overall progression-free survival of cancer cases with and without 1127 
MET alterations. 1128 
 1129 
 1130 
  1131 
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Table 1. Summary of MET inhibitors in use and in development. 1132 
43 
 
Compound name Company Targeted kinase(s) 
Crizotinib (PF-02341066) Pfizer (New York City, 
New York, USA) 
MET, ALK, RON, AXL, TIE2, ROS1 
Cabozantinib (XL184) Exelixis (Alameda, 
California, USA) 
MET, RET, VEGFR1-3, KIT, FLT3, 
TIE2, TRKB, AXL 
Foretinib (XL880) Exelixis/GlaxoSmithKline 
(London, UK) 
MET, VEGFR2, RON, ERK, AKT, 
PDGFRβ, c-KIT, TIE2 
Glesatinib (MGCD265) MethylGene/Mirati 
Therapeutics (San Diego, 
California, USA) 
MET, RON, VEGFR1-2, PDGFR, KIT, 
FLT3, TIE2, AXL 
Golvatinib (E-7050) Eisai (Tokyo, Japan) MET, VEGFR2, RON, Eph, KIT 
Merestinib (LY2801653) Eli Lilly MET, MST1R, FLT3, AXL, MERTK, 
TIE2, ROS1, NTRK1/2/3, DDR1/2, 
MKNK1/2, VEGFR2 
PF-04217903 Pfizer MET, ALK 
AMG 208 Amgen MET, VEGFR1-3, RON, TIE2 
Capmatinib 
(INC280/INCB28060) 
Incyte (Wilmington, 
Delaware, USA) /Novartis 
(Basel, Switzerland) 
MET 
Tepotinib (EMD1214063) EMD Serono (Darmstadt, 
Germany) 
MET 
AMG 337 Amgen MET 
Savolitinib/Volitinib 
(AZD6094) 
AstraZeneca (Cambridge, 
UK) 
MET 
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OMO-1 (JNJ-38877618) Johnson & Johnson (New 
Brunswick, New Jersey, 
USA) 
ME 
 1133 
